Ibogaine and Their Analogs as Therapeutics for Neurological and Psychiatric Disorders.

Abstract

ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXTIbogaine and Their Analogs as Therapeutics for Neurological and Psychiatric DisordersRobert B. Kargbo*Robert B. KargboUsona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States*[email protected]More by Robert B. Kargbohttps://orcid.org/0000-0002-5539-6343Cite this: ACS Med. Chem. Lett. 2022, 13, 6, 888–890Publication Date (Web):May 26, 2022Publication History Received6 May 2022Published online26 May 2022Published inissue 9 June 2022https://pubs.acs.org/doi/10.1021/acsmedchemlett.2c00214https://doi.org/10.1021/acsmedchemlett.2c00214editorialACS PublicationsCopyright © Published 2022 by American Chemical Society. This publication is available under these Terms of Use. Request reuse permissions This publication is free to access through this site. Learn MoreArticle Views5414Altmetric-Citations-LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail PDF (656 KB) Get e-AlertscloseSUBJECTS:Amines,Diseases and disorders,Peptides and proteins,Pharmaceuticals,Receptors Get e-Alerts